However, low expression of PD-L1 might not be the major criteria for the impaired response to immunotherapy, since a retrospective study on NSCLC patients reveal that LKB1 mutant tumors that have high PDL1 expression are also refractory to ICB (125). The gene discussed is CD274; the disease is non-small cell lung carcinoma.